Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.74) by $0.12. The firm earned $0.10 million during the quarter, compared to the consensus estimate of $0.02 million. Intra-Cellular Therapies had a negative return on equity of 29.74% and a negative net margin of 27,180.94%. During the same period in the prior year, the company posted ($0.64) earnings per share. View Intra-Cellular Therapies' Earnings History.

9 brokerages have issued 1 year target prices for Intra-Cellular Therapies' shares. Their forecasts range from $10.00 to $75.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $33.14 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

• 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/16/2017)
• 2. Cantor Fitzgerald analysts commented, "March FDA meeting could highlight path forward. Management noted that a meeting with the FDA is planned for late March, at which submission of the NDA will be discussed. We expect the company to have no specific commentary until the meeting minutes have been reviewed. If a plan to file is announced, we believe the market could de-risk the program to a level lower than that after the first Phase 3 trial data were released. Key to FDA approval will clearly be the robustness of the data presented to the Agency. The track record for schizophrenia drug programs is that not all trials are successful. Third Phase 3 bipolar depression trial in the works. Management noted that a third Phase 3 trial in bipolar depression will be conducted to optimize potential success." We believe such a strategy makes sense considering that, like schiophrenia clinical trials, some failure is not unusual. With an extra" clinical trial ongoing, were one to fail, we believe it reasonable that an NDA would still be filable. Enrollment is expected to complete by the end of 2018." (3/2/2017)
• 3. Cowen and Company analysts commented, "Today ITCI reported 4Q16 results." (3/1/2017)
• 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Some companies that are related to Intra-Cellular Therapies include Insmed (INSM), Acorda Therapeutics (ACOR), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), NeuroDerm (NDRM), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), ZIOPHARM Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Epizyme (EPZM), Aclaris Therapeutics (ACRS), Flexion Therapeutics (FLXN), Retrophin (RTRX), La Jolla Pharmaceutical Company (LJPC), PTC Therapeutics (PTCT) and Vanda Pharmaceuticals (VNDA).

Intra-Cellular Therapies' management team includes the folowing people:

• Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary
• Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer
• Michael I. Halstead, Senior Vice President, General Counsel, Secretary
• Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development
• Juan F. Sanchez M.D., Vice President - Corporate Communications
• Allen A. Fienberg Ph.D., Vice President - Business Development
• Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer
• Christopher D. Alafi Ph.D., Independent Director
• Richard Alan Lerner M.D., Independent Director
• Joel S. Marcus J.D. CPA, Independent Director

Intra-Cellular Therapies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Street Advisors Inc. NC (0.04%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $12.58.